| abstract |
Disclosed is the use of an antibody for the preparation of a pharmaceutical composition for the treatment of cancer, wherein the antibody specifically binds the human G250 antigen, wherein the antibody has been glycoengineered to have an increased proportion of bisected hybrid oligosaccharides or galactosylated complex oligosaccharides in the Fc region, and wherein the antibody has increased antibody-dependent cellular cytotoxicity as a result of the glycoengineering. |